Total submissions: 1
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ambry Genetics | RCV000564962 | SCV000663538 | uncertain significance | Hereditary cancer-predisposing syndrome | 2019-05-06 | criteria provided, single submitter | clinical testing | The p.V32I variant (also known as c.94G>A), located in coding exon 2 of the PMS2 gene, results from a G to A substitution at nucleotide position 94. The valine at codon 32 is replaced by isoleucine, an amino acid with highly similar properties. This amino acid position is highly conserved in available vertebrate species. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |